A Phase 4 interventional study of Esketamine hydrochloride in Esketamine, Sepsis and Inflammatory Response, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Terminated at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Phase 4, Interventional, and Treatment
Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 120th largest by enrollment of the 121 interventional ones that give a count, is one of 27 that started in 2021, is one of 17 in phase 4, and was the 129th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 27 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology has 8 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Studies have shown that excessive systemic inflammatory response and concomitant immunosuppression are the main cause of early death in patients with sepsis. Therefore, it is very important to reduce excessive inflammation and improve immunosuppression in the acute phase of sepsis. Clinical studies have shown that esketamine combined with propofol for sedation has been proven to be safe and effective for septic patients in the ICU due to its cardiovascular stability. Previous studies have demonstrated that esketamine has anti-inflammatory effects against depression and surgical stress. Our preliminary experimental studies have found that esketamine had strong anti-inflammatory effects in the acute phase of sepsis. However, it is not clear whether esketamine could reduce excessive inflammation and improve immunosuppression in septic patients primarily sedated with a continuous infusion of propofol.
This intervention study is to investigate whether three consecutive days of intravenous esketamine infusions via infusion pump (0.07 mg/kg/h) could reduce excessive inflammation and improve immunosuppression in septic patients requiring mechanical ventilation in the ICU under sedation primarily with propofol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2). After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Drug: Esketamine hydrochloride
After inclusion, patients are sedated primarily with propofol (0-3 mg/kg/h) using a microinfusion pump and adjusted according to the depth of sedation (Richmond Agitation Sedation Scale (RASS): 0 to -2).
After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.
Serum concentration of inflammatory cytokines (0 h)
Interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-2, IL-4, IL-10, IL-17A, and interferon (IFN)-γ
Time frame: 0 hour after study inclusion
Serum concentration of inflammatory cytokines (48 h)
IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ
Time frame: 48 hours after study inclusion
Serum concentration of inflammatory cytokines (72 h)
IL-6, TNF-α, IL-2, IL-4, IL-10, IL-17A, and IFN-γ
Time frame: 72 hours after study inclusion
Absolute number of lymphocyte subsets in the peripheral blood (0 h)
CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells
Time frame: 0 hour after study inclusion
Absolute number of lymphocyte subsets in the peripheral blood (48 h)
CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells
Time frame: 48 hours after study inclusion
Absolute number of lymphocyte subsets in the peripheral blood (72 h)
CD3(+), CD3(+) CD4(+), CD3(+) CD8(+), CD3(-) CD16(+) CD56(+) , and CD19(+) cells
Time frame: 72 hours after study inclusion
ICU length of stay
Length of stay in the ICU
Time frame: up to 8 weeks
Serum concentration of atrial natriuretic peptide (ANP) (0 h)
ANP is secreted primarily by atrial cardiomyocytes
Time frame: 0 hour after study inclusion
Serum concentration of atrial natriuretic peptide (ANP) (48h)
ANP is secreted primarily by atrial cardiomyocytes
Time frame: 48 hours after study inclusion
Serum concentration of atrial natriuretic peptide (ANP) (72h)
ANP is secreted primarily by atrial cardiomyocytes
Time frame: 72 hours after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 0 hour after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 24 hours after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 48 hours after study inclusion
Acute physiology and chronic health evaluation (APACHE) Ⅱ score
0-67, higher scores correspond to more severe disease and a higher risk of death
Time frame: 72 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 0 hour after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 24 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 48 hours after study inclusion
Sequential organ failure assessment (SOFA) score
0-43, higher scores correspond to more severe sepsis
Time frame: 72 hours after study inclusion
Mechanical ventilation time after inclusion
Patients requiring mechanical ventilation after study inclusion
Time frame: Up to 8 weeks
Total hospital length of stay
Total length of hospital stay
Time frame: Through study completion, an average of 2 year
Infection complications
Pulmonary infection, urinary tract infection, bloodstream infections, etc
Time frame: Through study completion, an average of 2 year
In-hospital mortality
Mortality rates for the entire period of hospitalization
Time frame: Through study completion, an average of 2 year
90-day readmission rate
Percentage of readmission to hospital within 90 days of study inclusion
Time frame: Through study completion, an average of 2 year
CCL1 expression in alveolar macrophages (0 h)
CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 0 hour after study inclusion
CCL1 expression in alveolar macrophages (24 h)
CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 24 hours after study inclusion
CCL1 expression in alveolar macrophages (72 h)
CCL1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 72 hours after study inclusion
expression of WNT pathway proteins in alveolar macrophages (0 h)
Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 0 hour after study inclusion
expression of WNT pathway proteins in alveolar macrophages (24 h)
Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 24 hours after study inclusion
expression of WNT pathway proteins in alveolar macrophages (72 h)
Wnt5a, FZD5, b-catenin, Lef1 expression in alveolar macrophages collected from bronchoalveolar lavage fluid
Time frame: 72 hours after study inclusion
Plan to share: Yes — After the completion of the study, the original data will be sent to the email address: zhjcheng1@163.com, and the password will be provided after the paper is published.
Supporting information: Clinical study report
Time frame: Six months after the paper was published
Access criteria: The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Jan 2026, 53 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Oct 2026 → Jan 2026 and completion Oct 2026 → Jan 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
Due to changes in the study plan, no significant clinical benefit was observed, but no adverse events occurred either.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →